Verrica Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Verrica Pharmaceuticals CEO'su Jayson Rieger, Nov2024 tarihinde atandı, in görev süresi 8.92 yıldır. şirketin hisselerinin 0.62% doğrudan sahiptir ve bu hisselerin değeri € 528.75K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 7.7 yıldır.

Anahtar bilgiler

Jayson Rieger

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jayson Rieger (48 yo)

no data

Görev süresi

Dr. Jayson M. Rieger, Ph D., M.B.A., is President, CEO & Director of Verrica Pharmaceuticals Inc. from November 5, 2024. Dr. Rieger serves as Non-Executive Independent Director at Lytix Biopharma AS since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Hayes	Chief Legal Officer	6.2yrs	US$2.56m	0.073% € 62.2k
Jayson Rieger	President	no data	Veri yok	0.62% € 528.7k
John Kirby	Interim CFO	no data	Veri yok	Veri yok
Gary Goldenberg	Chief Medical Officer	4.3yrs	US$989.18k	0.060% € 51.3k
Eugene Scavola	Executive Vice President of Technical Operations	5.1yrs	Veri yok	Veri yok
Bradley Catalone	Head of Drug Development	4.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: 1NE 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jayson Rieger	President	8.9yrs	Veri yok	0.62% € 528.7k
Mark Prygocki	Independent Director	6.5yrs	US$119.19k	0% € 0
Mark Lebwohl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lawrence F. Eichenfield	Independent Director	4.3yrs	US$119.19k	0% € 0
Sean Stalfort	Director	8.9yrs	Veri yok	0.51% € 437.1k
Paul Manning	Chairman of the Board	8.9yrs	Veri yok	14.96% € 12.8m
Ted White	Director	6.5yrs	US$3.50m	0.11% € 97.9k
Steven Cohen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Elaine Siegfried	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Anthony Mancini	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Janice Pelletier	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Greenberg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1NE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Verrica Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Announces Board and Committee Changes

Chief Financial Officer recently sold €69k worth of stock

President recently sold €212k worth of stock

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Chief Financial Officer recently sold €76k worth of stock

Recent updates

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering.

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering.

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Announces Board and Committee Changes

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Chief Financial Officer recently sold €69k worth of stock

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.24 loss in 2Q 2023)

No longer forecast to breakeven

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 14, 2024

President recently sold €212k worth of stock

New major risk - Share price stability

Verrica Pharmaceuticals Inc. Announces Litigation Settlement with Dormer Laboratories, Inc

First quarter 2024 earnings released: US$0.44 loss per share (vs US$0.15 loss in 1Q 2023)

New major risk - Financial position

Verrica Pharmaceuticals Inc. to Report Q1, 2024 Results on May 13, 2024

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Forecast to breakeven in 2026

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$1.48 loss per share (vs US$0.72 loss in FY 2022)

Verrica Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services

Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™? for the Treatment of Common Warts

Forecast to breakeven in 2026

Chief Financial Officer recently sold €76k worth of stock

New minor risk - Profitability

New minor risk - Profitability

Verrica Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2022)

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting

Insufficient new directors

Chairman of the Board recently bought €907k worth of stock

New major risk - Share price stability

Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Forecast to breakeven in 2025

No longer forecast to breakeven

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.31 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.72 loss per share (vs US$1.30 loss in FY 2021)

Forecast to breakeven in 2025

Verrica Pharmaceuticals Inc. Resubmits New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.47 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.43 loss in 2Q 2021)

Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Director recently bought €488k worth of stock

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $25.2 million.

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell 2000 Growth Index

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc

No longer forecast to breakeven

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Verrica Pharmaceuticals Inc. Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-In-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

No longer forecast to breakeven

Forecast to breakeven in 2024

Verrica Pharmaceuticals Inc. Announces Acceptance by FDA of NDA Resubmission for VP-102

Chairman of the Board recently bought €415k worth of stock

Verrica Pharmaceuticals Inc. Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Receives Complete Response Letter from the FDA Identifying Deficiencies At Facility of Contract Manufacturer for Its New Drug Application for Vp-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum